{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:00:08Z","timestamp":1785074408171,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971081"],"award-info":[{"award-number":["81971081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2024-6-52"],"award-info":[{"award-number":["320.6750.2024-6-52"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118122","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:18:29Z","timestamp":1780589909000},"page":"118122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Nitazoxanide cooperates with cytarabine to inhibit cytarabine-resistant acute myeloid leukemia progression via mitochondrial dysfunction and PLK1 suppression"],"prefix":"10.1016","volume":"251","author":[{"given":"Yue","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118122_b0005","doi-asserted-by":"crossref","unstructured":"D.A. Pollyea, J.K. Altman, R. Assi, D. Bixby, A.T. Fathi, J.M. Foran, I. Gojo, A.C. Hall, B.A. Jonas, A. Kishtagari, J. Lancet, L. Maness, J. Mangan, G. Mannis, G. Marcucci, A. Mims, K. Moriarty, M. Mustafa Ali, J. Neff, R. Nejati, R. Olin, M.E. Percival, A. Perl, A. Przespolewski, D. Rao, F. Ravandi, R. Shallis, P.J. Shami, E. Stein, R.M. Stone, K. Sweet, S. Thota, G. Uy, P. Vachhani, C.J. Cassara, D.A. Freedman-Cass, K. Stehman, Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 21(5) (2023) 503-513 http:\/\/doi.org\/10.6004\/jnccn.2023.0025.","DOI":"10.6004\/jnccn.2023.0025"},{"issue":"2","key":"10.1016\/j.bcp.2026.118122_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.bcp.2026.118122_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.beha.2019.05.007","article-title":"Clonal hematopoiesis and risk of acute myeloid leukemia","volume":"32","author":"Desai","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/10428194.2022.2136960","article-title":"Lower intensity regimens for acute myeloid leukemia: opportunities and challenges","volume":"64","author":"Ahmed","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.bcp.2026.118122_b0025","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4103\/0973-1482.187369","article-title":"Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: a single center experience","volume":"14","author":"Onec","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.bcp.2026.118122_b0030","doi-asserted-by":"crossref","unstructured":"M.W. Drummond, Developments in chemotherapy for the treatment of acute myeloid leukemia, Int J Hematol Oncol 8(2) (2019) Ijh16 http:\/\/doi.org\/10.2217\/ijh-2019-0004.","DOI":"10.2217\/ijh-2019-0004"},{"issue":"S1","key":"10.1016\/j.bcp.2026.118122_b0035","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.5045\/br.2020.S003","article-title":"New agents in acute myeloid leukemia (AML)","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res"},{"issue":"10","key":"10.1016\/j.bcp.2026.118122_b0040","first-page":"1342","article-title":"Treatment of high-risk acute myeloid leukemia","volume":"66","author":"Masamoto","year":"2025","journal-title":"Rinsho Ketsueki"},{"issue":"7","key":"10.1016\/j.bcp.2026.118122_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35806","article-title":"Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges","volume":"131","author":"Senapati","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118122_b0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel therapeutic targets in acute myeloid leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118122_b0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41419-025-07653-6","article-title":"Mechanisms of chemotherapy failure in refractory\/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism","volume":"16","author":"Yeon Chae","year":"2025","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bcp.2026.118122_b0065","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.118122_b0070","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1194\/jlr.RA119000251","article-title":"Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells","volume":"60","author":"Kao","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2026.118122_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118122_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111176","article-title":"Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo","volume":"400","author":"Yang","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2026.118122_b0085","doi-asserted-by":"crossref","unstructured":"N.M. Abd El-Fadeal, M.S. Nafie, K.E.-K. M, A. El-Mistekawy, H.M.F. Mohammad, A.M. Elbahaie, A.A. Hashish, S.Y. Alomar, S.Y. Aloyouni, M. El-Dosoky, K.M. Morsy, S.A. Zaitone, Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt\/\u03b2-Catenin Signaling Inhibition, Int J Mol Sci 22(10) (2021) http:\/\/doi.org\/10.3390\/ijms22105213.","DOI":"10.3390\/ijms22105213"},{"issue":"7","key":"10.1016\/j.bcp.2026.118122_b0090","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118122_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114588","article-title":"Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer","volume":"190","author":"Sun","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118122_b0100","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/hsz-2022-0148","article-title":"Nitazoxanide inhibits osteosarcoma cells growth and metastasis by suppressing AKT\/mTOR and Wnt\/\u03b2-catenin signaling pathways","volume":"403","author":"Ye","year":"2022","journal-title":"Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118122_b0105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41417-020-00239-8","article-title":"Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand","volume":"28","author":"Yu","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118122_b0110","article-title":"Nitazoxanide modulates mitochondrial function and inflammatory metabolism in chondrocytes from patients with osteoarthritis via AMPK\/mTORC1 signaling","volume":"14","author":"Kim","year":"2025","journal-title":"Antioxidants (basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0115","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1038\/s41598-022-12519-4","article-title":"Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma","volume":"12","author":"Ek","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118122_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115121","article-title":"Kaempferol improves mitochondrial homeostasis via mitochondrial dynamics and mitophagy in diabetic kidney disease","volume":"162","author":"Xia","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41598-024-84021-y","article-title":"Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS\/JNK\/p38 MAPK signaling pathway in multiple myeloma","volume":"15","author":"Gao","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.118122_b0130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41419-023-05587-5","article-title":"HIF1\u03b1-BNIP3-mediated mitophagy protects against renal fibrosis by decreasing ROS and inhibiting activation of the NLRP3 inflammasome","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118122_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2023.115717","article-title":"Melatonin alleviates particulate matter-induced liver fibrosis by inhibiting ROS-mediated mitophagy and inflammation via Nrf2 activation","volume":"268","author":"Zhu","year":"2023","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molcel.2018.05.026","article-title":"DNA replication determines timing of mitosis by restricting CDK1 and PLK1 activation","volume":"71","author":"Lemmens","year":"2018","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118122_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102887","article-title":"Polo-like kinase 1 (PLK1) O-GlcNAcylation is essential for dividing mammalian cells and inhibits uterine carcinoma","volume":"299","author":"Yan","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2026.118122_b0150","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.1021\/acs.jmedchem.2c00614","article-title":"Polo-like Kinase 1 inhibitors in human cancer therapy: development and therapeutic potential","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118122_b0155","doi-asserted-by":"crossref","unstructured":"K. Akopyan, Z. Hao, A. Lindqvist, Preparation for mitosis requires gradual CDK1 activation, iScience 28(5) (2025) 112292 http:\/\/doi.org\/10.1016\/j.isci.2025.112292.","DOI":"10.1016\/j.isci.2025.112292"},{"issue":"10","key":"10.1016\/j.bcp.2026.118122_b0160","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1080\/15384101.2020.1749471","article-title":"CDK1-PLK1\/SGOL2\/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma","volume":"19","author":"Li","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2026.118122_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.768879","article-title":"Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1\/CCNB1\/PLK1 signaling","volume":"11","author":"Yi","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.20517\/cdr.2022.133","article-title":"Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment","volume":"6","author":"Tabe","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.bcp.2026.118122_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bjh.16044","article-title":"SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation","volume":"187","author":"Ma","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2026.118122_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217990","article-title":"Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis","volume":"633","author":"Ghosh","year":"2025","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.bcp.2026.118122_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115317","article-title":"Molecular mechanisms of biochanin a in AML Cells: apoptosis induction and pathway-specific regulation in U937 and THP-1","volume":"26","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118122_b0190","doi-asserted-by":"crossref","unstructured":"A.S. Sheth, K.K. Chan, S. Liu, J. Wan, S.P. Angus, S.D. Rhodes, D.K. Mitchell, C. Davis, M. Ridinger, P.J. Croucher, A.M. Zeidan, A. Wijeratne, S. Qian, N.T. Tran, E.A. Sierra Potchanant, PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia, Cancer Res Commun 5(4) (2025) 648-667 http:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0260.","DOI":"10.1158\/2767-9764.CRC-24-0260"},{"issue":"2","key":"10.1016\/j.bcp.2026.118122_b0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/2040620715571077","article-title":"Targeting polo-like kinase 1 in acute myeloid leukemia","volume":"6","author":"Brandwein","year":"2015","journal-title":"Ther. Adv. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118122_b0200","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2159-8290.CD-20-1227","article-title":"Mitochondrial and metabolic pathways regulate nuclear gene expression to control differentiation stem cell function, and immune response in leukemia","volume":"11","author":"Egan","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:11:48Z","timestamp":1785071508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0006295226004570"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118122","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitazoxanide cooperates with cytarabine to inhibit cytarabine-resistant acute myeloid leukemia progression via mitochondrial dysfunction and PLK1 suppression","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118122"}}